View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioera 配当と自社株買い配当金 基準チェック /06Bioera現在配当金を支払っていません。主要情報0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€810.5k market cap, or US$845.1k). Minor Risk Shareholders have been diluted in the past year (8.1% increase in shares outstanding).New Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).Is New 90 Day High Low • Mar 04New 90-day low: €0.25The company is down 12% from its price of €0.28 on 04 December 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 16% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €0.26The company is down 31% from its price of €0.37 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: €0.26The company is down 35% from its price of €0.40 on 20 August 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.Is New 90 Day High Low • Oct 27New 90-day low: €0.29The company is down 30% from its price of €0.41 on 29 July 2020. The Italian market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 06New 90-day low: €0.32The company is down 33% from its price of €0.47 on 08 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period.決済の安定と成長配当データの取得安定した配当: BIEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BIEの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Bioera 配当利回り対市場BIE 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BIE)0%市場下位25% (IT)1.7%市場トップ25% (IT)4.5%業界平均 (Personal Products)2.6%アナリスト予想 (BIE) (最長3年)n/a注目すべき配当: BIEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BIEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BIE Italian市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: BIEが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/29 06:34終値2025/04/22 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioera S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€810.5k market cap, or US$845.1k). Minor Risk Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
New Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.
Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).
Is New 90 Day High Low • Mar 04New 90-day low: €0.25The company is down 12% from its price of €0.28 on 04 December 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 16% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €0.26The company is down 31% from its price of €0.37 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: €0.26The company is down 35% from its price of €0.40 on 20 August 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Oct 27New 90-day low: €0.29The company is down 30% from its price of €0.41 on 29 July 2020. The Italian market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 06New 90-day low: €0.32The company is down 33% from its price of €0.47 on 08 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period.